PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rasagiline mesilate - Parkinson's disease
PAD Profile : Rasagiline mesilate - Parkinson's disease
Keywords :
Parkinsons disease, PD, monoamine-oxidase-B inhibitors, MAOB
Brand Names Include :
Azilect
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Orphenadrine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
- Monoamine-oxidase-B inhibitors (rasagiline, selegiline), (or levodopa or dopamine agonists) are a first-line treatment option in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
- Monoamine-oxidase-B inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.
Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.
Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Modifications to therapy should only be carried out on specialist advice.
Prescribers are reminded to prescribe generically and not by brand.
Associated BNF Codes
04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism